Claims
- 1. An isolated polynucleotide which codes for a domain of a transcription factor, wherein the domain confers to the transcription factor susceptibility to degredation under normoxia conditions.
- 2. The polynucleotide of claim 1, which codes for a domain of HIF1-alpha.
- 3. The polynucleotide of claim 2, wherein the domain comprises amino acids between residues 530 to 603 of the HIF1-alpha.
- 4. The polynucleotide of claim 2, wherein the domain comprises amino acids 530 to 603 of the HIF1-alpha.
- 5. The polynucleotide of claim 2, wherein the domain is amino acids 530 to 603 of the HIF1-alpha.
- 6. A chimeric transactivator comprising a domain of a transcription factor, wherein the domain confers to the transcription factor susceptibility to degradation under normoxia conditions.
- 7. The transactivator of claim 6, which comprises the tetracycline transactivator protein.
- 8. The transactivator of claim 7, wherein the transcription factor is HIF1-alpha.
- 9. The transactivator of claim 8, wherein the domain comprises amino acids between residues 530 to 603 of the HIF1-alpha.
- 10. The transactivator of claim 8, wherein the domain comprises amino acids 530 to 603 of the HIF1-alpha.
- 11. The transactivator of claim 8, wherein the domain is amino acids 530 to 603 of the HIF1-alpha.
- 12. An isolated polynucleotide which codes for the chimeric transactivator of claim 6.
- 13. The polynucleotide of claim 12, wherein the chimeric transactivator comprises the tetracycline transactivator protein.
- 14. The polynucleotide of claim 12, wherein the transcription factor is HIF1-alpha.
- 15. The polynucleotide of claim 14, wherein the domain comprises amino acids between residues 530 to 603 of the HIF1-alpha.
- 16. The polynucleotide of claim 14, wherein the domain comprises amino acids 530 to 603 of the HIF1-alpha.
- 17. A vector comprising the polynucleotide of claim 12.
- 18. The vector of claim 17, wherein the chimeric transactivator comprises the tetracycline transactivator protein.
- 19. The vector of claim 17, wherein the transcription factor is HIF1-alpha.
- 20. The vector of claim 19, wherein the domain comprises amino acids between residues 530 to 603 of the HIF1-alpha.
- 21. The vector of claim 19, wherein the domain comprises amino acids 530 to 603 of the HIF1-alpha.
- 22. A composition, comprising:
(c) the polynucleotide of claim 12 and (d) a polynucleotide which contains a sequence that codes for a target gene and a promoter which is regulated by the chimeric tranactivator coded for by (a).
- 23. The composition of claim 22, wherein the chimeric transactivator comprises the tetracycline transactivator protein.
- 24. The composition of claim 22, wherein the transcription factor is HIF1-alpha.
- 25. The composition of claim 24, wherein the domain comprises amino acids between residues 530 to 603 of the HIF1-alpha.
- 26. The composition of claim 24, wherein the domain comprises amino acids 530 to 603 of the HIF1-alpha.
- 27. The composition of claim 22, wherein the target gene is erythropoietin.
- 28. The composition of claim 22, wherein the target gene is VEGF.
- 29. A method of expressing a target gene in a subject, comprising administering the composition of claim 22 to the subject.
- 30. The method of claim 29, wherein the subject is a mammal.
- 31. The method of claim 29, wherein the subject is a human.
- 32. The composition of claim 29, wherein the target gene is erythropoietin.
- 33. The composition of claim 29, wherein the target gene is VEGF.
- 34. A method of expressing a target gene in a subject, comprising administering the composition of claim 23 to the subject.
- 35. A method of expressing a target gene in a subject, comprising administering the composition of claim 24 to the subject.
- 36. A method of expressing a target gene in a subject, comprising administering the composition of claim 25 to the subject.
- 37. A method of expressing a target gene in a subject, comprising administering the composition of claim 26 to the subject.
- 38. A method of increasing the number of red blood cells in a subject, comprising administering an effective amount of the composition of claim 27 to the subject.
- 39. The method of claim 38, wherein the subject is a mammal.
- 40. The method of claim 38, wherein the subject is a human.
- 41. A method of increasing the number of blood vessels in a subject, comprising administering an effective amount of the composition of claim 28 to the subject.
- 42. The method of claim 41, wherein the subject is a mammal.
- 43. The method of claim 41, wherein the subject is a human.
CONTINUING APPLICATION INFORMATION
[0001] This application claims benefit of U.S. provisional application serial No. 60/376,269, filed on Apr. 30, 2002, and incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60376269 |
Apr 2002 |
US |